[Skip to Content]

Upstate Active Clinical Trials

Study Title:

AALL1732 - A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND# 133494, NSC# 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

What is the purpose of the study? (in Layman's terms, please describe the study)

Trial of Inotuzumab Ozogamicin (IND# 133494, NSC# 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Upstate Institutional Review Board (IRB) Number:

1521725

Study/Protocol ID:

AALL1732

Study Phase:

III

Patient Age Group:

Children

Principal Investigator:

Melanie A Comito

Who is eligible?

Patients must be > 365 days and < 25 years of age

What is involved if I participate?

  • How long is the study?
    until accrual is met
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    blood draws, lumbar puncture, bone marrow biopsy/aspirate

Where will the study take place?

SUNY Upstate Medical University

Other Information:

N/A

Who can I contact for more information?

Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]

Return to Previous Page || Search Again

Top